

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

**RE-DESIGNATION OF EXECUTIVE DIRECTORS AS
NON-EXECUTIVE DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Lian Yong CHEN (“**Dr. Chen**”) and Dr. Wei LI (“**Dr. Li**”) have been re-designated from executive Directors to non-executive Directors with effect from July 20, 2021 as they wish to focus more on the strategic management and planning of the Group without being distracted by the daily management. Dr. Chen will remain as the Chairman of the Board after the re-designation as a non-executive Director.

Dr. Chen, aged 58, has been the Chairman of the Board and a Director since May 23, 2018. He was appointed as a non-executive Director on May 23, 2018 and was re-designated as an executive Director on April 28, 2020. Dr. Chen has over 20 years of experience in the life sciences industry. He is currently the founding managing partner and CEO of 6 Dimensions Capital and the founder and managing partner at Frontline BioVentures. Since May 2019, Dr. Chen has served as a director of 111, Inc. (111集團), a company whose shares are listed on NASDAQ (ticker symbol: YI). He was appointed as a non-executive director of Hua Medicine (華領藥業), a company whose shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 2552), in January 2015 and served as a director of Hua Medicine Technology (Hong Kong) Limited (華領醫藥技術(香港)有限公司) since then. From October 29, 2018 to July 9, 2021, he served as a non-executive director at CStone Pharmaceuticals (基石藥業), a company whose shares are listed on the Stock Exchange (stock code: 2616). Since December 2014, he has served as a director of Shanghai Hile Bio-Technology Co. Ltd. (上海海利生物技術股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 603718). From April 2014 to April 2016 and from August 2018 onwards, Dr. Chen served as a director at Hua Medicine (Shanghai) Co. Ltd. (華領醫藥技術(上海)有限公司). From May 2008 to March 2014, Dr. Chen served as a partner at FIL Capital Management (Hong Kong) Limited in Asia. Dr. Chen conducted postdoctoral research in chemistry at the Massachusetts Institute of Technology in the United States from August 1991 to December 1992 after obtaining his Ph.D. in chemistry (with top honor) from the University of Louvain, located in Louvain-la-Neuve, Belgium, in June 1991. He graduated from Peking University (北京大學) majoring in chemistry in Beijing, China in July 1984.

Dr. Li, aged 49, has been a Director since April 13, 2018. He was appointed as a non-executive Director on April 13, 2018 and was re-designated as an executive Director on April 28, 2020. Dr. Li has over 20 years of experience in the biotech industry. He is a founding partner of Creacion Ventures L.P. He has served as the Managing Partner of 6 Dimensions Capital since October 2017 and is a founding partner and the managing partner at WuXi Healthcare Ventures since July 2015. He has also been a non-executive director of CStone Pharmaceuticals (基石藥業), a company whose shares are listed on the Stock Exchange (stock code: 2616) since October 2018. Dr. Li received a Ph.D. in chemistry from Harvard University in the United States in November 1998, and an MBA from the J. L. Kellogg School of Management at Northwestern University in the United States in June 2003. He graduated with a Bachelor of Science in chemical physics from the University of Science and Technology of China (中國科學技術大學) in Anhui, China in July 1993.

The Board considered and accepted the recommendation from the Company's Nomination Committee to re-designate Dr. Chen and Dr. Li as non-executive Directors, after reviewing their academic qualification, working experience and contributions to the Board during their tenures as executive Directors.

Each of Dr. Chen and Dr. Li have entered into a letter of appointment with the Company in relation to his appointment as non-executive Directors with an initial term of three years from July 10, 2020, being the date on which dealings in the shares of the Company first commence on the Main Board of the Stock Exchange, which may be terminated by either party giving a three-month prior written notice to the other party in writing. Each of Dr. Chen and Dr. Li will be subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company and as required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), or vacation from office pursuant to any applicable laws from time to time. Dr. Chen and Dr. Li will not receive any director's fee for their term of appointment as non-executive Directors.

As of the date of this announcement, save as disclosed herein, each of Dr. Chen and Dr. Li confirms that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas or any other major appointment and professional qualification in the past three years; (ii) he does not hold any other position with the Company or subsidiaries of the Company; (iii) he does not have any relationship with any directors, senior management or substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) he does not have, and is not deemed to have, interest or short positions in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, the Board is not aware of any other information in relation to the aforesaid re-designation of Dr. Chen and Dr. Li that is required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to the aforesaid re-designation.

By Order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, July 20, 2021

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive Directors.